多巴酚丁胺在新生儿持续肺动脉高压治疗中的应用分析

Application of Dobutamine in the Treatment of Neonatal Persistent Pulmonary Hypertension

目的:分析多巴酚丁胺在新生儿持续肺动脉高压治疗中的应用。方法:在2015年1月~2017年2月,选取某院新生儿持续肺动脉高压患儿48例,均分为对照组与观察组,对照组给予常规治疗,观察组给予多巴酚丁胺治疗,观察患儿CRP水平、BNP水平、D-D水平、血气分析指标、临床效果及不良反应发生情况。结果:观察组患儿CRP、BNP、D-D水平比对照组低,PaO_2、SaO_2水平比对照组高,PaCO_2水平比对照组低,临床效果比对照组高,P<0.05;不良反应发生情况与对照组相比差异较小,P>0.05。结论:在新生儿持续肺动脉高压治疗中,能有效降低CRP、BNP、D-D水平,减轻患儿炎症反应及血液高凝状态,具有较好的安全性,值得借鉴。

Objective:To analyze the application of dobutamine in the treatment of neonatal persistent pulmonary hypertension.Methods:48 cases of children with neonatal persistent pulmonary hypertension treated in a hospital from January 2015 to February 2017 were selected and divided into control group and observation group.The control group was given conventional treatment,and the observation group was given dobutamine treatment,then the CRP level,the BNP level,D-D level,blood gas analysis index,clinical effect,and the incidence of adverse reactions in the two groups were observed.Results:The levels of CRP,BNP,and D-D in the observation group were lower than those in the control group,and the levels of PaO_2,SaO_2 in the observation group were higher than those in the control group.The PaCO_2 level in the observation group was lower than that in the control group,and the clinical effect was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:In the treatment of neonatal pulmonary hypertension,dobutamine can effectively reduce the CRP,BNP,D-D levels,alleviate inflammatory reaction and hypercoagulant state of blood in children,which has good safety and is worthy of reference.